EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 922 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Thinking outside the box to tackle an aggressive children’s cancer September 8, 2021 Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t... December 19, 2024 ESMO Clinical Practice Guideline Express Update on the adoption of physical... January 27, 2026 Newly Discovered ‘Don’t Eat Me’ Signal May be a Target for... August 20, 2019 Load more HOT NEWS Reflections on Progress and Partnership at ASCO 2026 Rare Cancers Forum 2026: ESMO Leads European Efforts to Turn Evidence... Study Shows that Disrupted Gut Bacteria May Contribute to the Spread... 97-Year-Old Cancer Survivor Credits Her Success With Wanting To Attend A...
